NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Cocrystal Pharma, Inc. (COCP) Stock Analysis

Cocrystal Pharma, Inc. (COCP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

COCP

$1.13

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare COCP with… →

COCP Key Statistics

As of Sep 4, 2026
Trading
Open
$1.12
Previous Close
$1.13
Day's Range
1.10–1.14
52-Week Range
0.76–2.67
Volume
42.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.48
Valuation
Market Cap
$21.77M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
65.96
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.75
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$8.83M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
19.26M
1-Year Return
−22.60%
Dividend and dates
Avg Volume
61.78K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

COCP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+15.31%
2025−51.49%
2024+17.44%
2023−11.79%
2022−75.00%
2021−52.21%
2020+172.00%
2019−86.11%
2018−40.00%
2017−48.72%
2016 (partial year)−13.33%

As of September 4, 2026.

COCP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$8.83M—
2024$0.00−$17.50M—
2023$0.00−$17.98M—
2022$0.00−$38.84M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$9.02M−$8.83M—
2024$0.00—−$17.88M−$17.50M—
2023$0.00—−$21.16M−$17.98M—
2022$0.00—−$18.14M−$38.84M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

COCP Valuation vs Biotechnology Median

Median of 656 stocks
MetricCOCPBiotechnology medianvs median
P/S ratio65.9615.264.3x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cocrystal Pharma, Inc. (COCP) is capitalised at $21.77M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 10.

The most recent close on file for COCP is $1.13, dated September 4, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $0.76 to $2.67. The latest close sits 48.68% above that 52-week low.

Financial Health

In fiscal 2025, Cocrystal Pharma, Inc. reported revenue of $0.00. The same year closed with a net loss of $8.83M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.75.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 65.96 times revenue. On price-to-sales that is 4.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −22.60%. Across 10 years the annualized return works out at −39.89%. Beta against the wider market is reported at 1.48. Annualized volatility over the trailing 10 years is 110.24%.

Growth & Income

The record shows no dividend for COCP.

The strongest complete calendar year on file is 2020 at +172.00%; the weakest is 2019 at −86.11%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the price is +15.31%.

Peer Comparison

Cocrystal Pharma, Inc. (COCP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cocrystal Pharma, Inc. COCP $21.77M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Cocrystal Pharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.

Visit website →